PMID- 34512027
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220426
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 13
DP  - 2021
TI  - MALAT-1 is Associated with the Doxorubicin Resistance in U-2OS Osteosarcoma 
      Cells.
PG  - 6879-6889
LID - 10.2147/CMAR.S304922 [doi]
AB  - PURPOSE: Our study aimed to investigate the relationship between MALAT-1 
      (metastasis-associated lung adenocarcinoma transcript 1) expression and the 
      chemotherapy drug resistance in osteosarcoma. METHODS: The U-2OS osteosarcoma 
      cell line was selected for the experiment. The cells were treated with 
      methotrexate, doxorubicin, cisplatin, and ifosfamide, respectively. RT-PCR was 
      applied to detect the MALAT-1 expression in cells. The doxorubicin-resistant cell 
      line was constructed. The cells were divided into doxorubicin-sensitivity group 
      (DS/shCtrl), doxorubicin-resistance group (DR/shCtrl) and 
      shMALAT1-doxorubicin-resistance group (DR/shMALAT1). The colony formation assay 
      and 5-ethynyl-2'-deoxyuridine (EdU) assay were used to detect cell proliferation. 
      PI staining was used to detect the cell cycle. Transwell assay and wound healing 
      assay were used to observe the migration and invasion ability. Annexin V-FITC 
      assay was used to detect cell apoptosis. Western blot was used to detect the 
      protein expression and potential mechanism. The impacts of MALAT-1 expression 
      were verified in vivo. RESULTS: The MALAT-1 was upregulated in the 
      doxorubicin-resistant U-2OS osteosarcoma cells. Downregulating MALAT-1 in the 
      doxorubicin-resistant cells inhibited the proliferation, migration, and 
      invasiveness, increased the ratio of cells in the G0/G1 phase, promoted 
      apoptosis. In the doxorubicin-resistant U-2OS cells, the extracellular regulated 
      protein kinases (ERK) phosphorylation was declined, which could be reversed by 
      downregulating MALAT-1. In vivo assay indicated that the growth of 
      doxorubicin-resistant solid osteosarcoma could be suppressed by downregulating 
      MALAT-1. CONCLUSION: Our study provides evidence that doxorubicin may upregulate 
      MALAT-1 in osteosarcoma. Downregulating MALAT-1 in the doxorubicin resistance 
      U-2OS cells could reverse the resistance and may improve chemotherapeutic 
      efficiency. Some conclusions in previous literature may be one-sided.
CI  - (c) 2021 Liu et al.
FAU - Liu, Chang
AU  - Liu C
AD  - Department of Orthopedics, The 900th Hospital of Joint Logistic Support Force, 
      Fuzhou, Fujian Province, 350025, People's Republic of China.
AD  - Department of Orthopedics, Changhai Hospital Affiliated to the Naval Medical 
      University, Shanghai, 200433, People's Republic of China.
FAU - Han, Xuesong
AU  - Han X
AD  - Department of Orthopedics, The 900th Hospital of Joint Logistic Support Force, 
      Fuzhou, Fujian Province, 350025, People's Republic of China.
FAU - Li, Bo
AU  - Li B
AD  - Department of Orthopedics, Changhai Hospital Affiliated to the Naval Medical 
      University, Shanghai, 200433, People's Republic of China.
FAU - Huang, Shaobin
AU  - Huang S
AD  - Department of Orthopedics, The 900th Hospital of Joint Logistic Support Force, 
      Fuzhou, Fujian Province, 350025, People's Republic of China.
FAU - Zhou, Zhong
AU  - Zhou Z
AD  - Department of Orthopedics, The 900th Hospital of Joint Logistic Support Force, 
      Fuzhou, Fujian Province, 350025, People's Republic of China.
FAU - Wang, Zhiwei
AU  - Wang Z
AD  - Department of Orthopedics, Changhai Hospital Affiliated to the Naval Medical 
      University, Shanghai, 200433, People's Republic of China.
FAU - Wang, Wanming
AU  - Wang W
AD  - Department of Orthopedics, The 900th Hospital of Joint Logistic Support Force, 
      Fuzhou, Fujian Province, 350025, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20210901
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC8421671
OTO - NOTNLM
OT  - MALAT-1
OT  - chemotherapy resistance
OT  - doxorubicin
OT  - extracellular regulated protein kinases
OT  - long noncoding RNA
OT  - osteosarcoma
COIS- The authors report no conflicts of interest in this work.
EDAT- 2021/09/14 06:00
MHDA- 2021/09/14 06:01
PMCR- 2021/09/01
CRDT- 2021/09/13 06:38
PHST- 2021/02/02 00:00 [received]
PHST- 2021/08/18 00:00 [accepted]
PHST- 2021/09/13 06:38 [entrez]
PHST- 2021/09/14 06:00 [pubmed]
PHST- 2021/09/14 06:01 [medline]
PHST- 2021/09/01 00:00 [pmc-release]
AID - 304922 [pii]
AID - 10.2147/CMAR.S304922 [doi]
PST - epublish
SO  - Cancer Manag Res. 2021 Sep 1;13:6879-6889. doi: 10.2147/CMAR.S304922. eCollection 
      2021.